• Cardium Therapeutics (San Diego) said that data from the company's Matrix Phase 2b clinical study has been accepted for publication in the journal, Wound Repair and Regeneration and provided an update on plans for commercialization of its Excellagen formulated collagen topical wound dressing. The clinical paper now accepted for publication is titled, “Formulated Collagen Gel Accelerates Healing Rate Immediately after Application in Patients with Diabetic Neuropathic Foot Ulcers,“ and was authored by nine investigators who participated in the Matrix study and Cardium researchers and is expected to be published in early 2011. Excellagen formulated collagen topical gel wound care dressing was studied in a controlled, double blind Matrix Phase 2b clinical study of chronic diabetic lower extremity ulcers. Wounds treated with the Excellagen formulated collagen (2.6%) topical gel showed a statistically significant acceleration of wound healing during the first week following a one-time application compared to patients receiving standard of care therapy, a response that was sustained over a 14 day period. The authors suggest that more frequent applications of Cardium's Excellagen product candidate hold promise to significantly improve overall incidence of complete wound closure.